Ignite Creation Date:
2024-10-25 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06623955
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-09-24
Brief Title:
Maternal Serum Stathmin-1 Levels in Preeclampsia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Comparative Study of Maternal Serum Stathmin-1 Levels in Pregnancies With Preeclampsia Severe Preeclampsia and Healthy Controls
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study investigates maternal serum Stathmin-1 STMN-1 levels in pregnancies complicated by preeclampsia and severe preeclampsia compared to healthy pregnancies The aim is to explore potential differences in STMN-1 levels among these groups to better understand its role in preeclampsia pathophysiology Maternal serum STMN-1 levels will be measured between 32-34 weeks of gestation and patients will be monitored until delivery to assess whether they develop preeclampsia or severe preeclampsia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None